High expression of LUM independently predicts poor prognosis in gastric cancer: a bioinformatics study combining TCGA and GEO datasets

References

• Appunni S, Anand V, Khandelwal M, Gupta N, Rubens M, Sharma A. 2019. Small leucine rich proteoglycans (decorin, biglycan and lumican) in cancer. Clin Chim Acta. 491:1–7.
   Web of Science ®Google Scholar
• Appunni S, Anand V, Khandelwal M, Seth A, Mathur S, Sharma A. 2017. Altered expression of small leucine-rich proteoglycans (decorin, biglycan and lumican): plausible diagnostic marker in urothelial carcinoma of bladder. Tumour Biol 39:1010428317699112.
   Google Scholar
• Binato R, Santos EC, Boroni M, Demachki S, Assumpcao P, Abdelhay E. 2018. A common molecular signature of intestinal-type gastric carcinoma indicates processes related to gastric carcinogenesis. Oncotarget. 9:7359–7371.
   Google Scholar
• Bonnans C, Chou J, Werb Z. 2014. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 15:786–801.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424.
   PubMed Web of Science ®Google Scholar
• Chakravarti S, Stallings RL, SundarRaj N, Cornuet PK, Hassell JR. 1995. Primary structure of human lumican (keratan sulfate proteoglycan) and localization of the gene (LUM) to chromosome 12q21.3-q22. Genomics. 27:481–488.
   Web of Science ®Google Scholar
• Chen L, Zhang Y, Zuo Y, Ma F, Song H. 2017. Lumican expression in gastric cancer and its association with biological behavior and prognosis. Oncol Lett. 14:5235–5240.
   Web of Science ®Google Scholar
• Chen S, Birk DE. 2013. The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly. FEBS J 280:2120–2137.
   PubMed Web of Science ®Google Scholar
• Coulson-Thomas VJ, Coulson-Thomas YM, Gesteira TF, de Paula CA A, Carneiro CR, Ortiz V, Toma L, Kao WW, Nader HB. 2013. Lumican expression, localization and antitumor activity in prostate cancer. Exp Cell Res. 319:967–981.
   Web of Science ®Google Scholar
• de Wit M, Belt EJ, Delis-van Diemen PM, Carvalho B, Coupé VM, Stockmann HB, Bril H, Beliën JA, Fijneman RJ, Meijer GA. 2013. Lumican and versican are associated with good outcome in stage II and III colon cancer. Ann Surg Oncol. 20(Suppl 3):S348–S359. Epub 2012/06/20.
   Google Scholar
• D’Onofrio MF, Brezillon S, Baranek T, Perreau C, Roughley PJ, Maquart FX, Wegrowski Y. 2008. Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican. Biochem Biophys Res Commun. 365:266–272.
   PubMed Web of Science ®Google Scholar
• Forghanifard MM, Ardalan Khales S, Javdani-Mallak A, Rad A, Farshchian M, Abbaszadegan MR. 2014. Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma. Med Oncol. 31:922.
   PubMed Web of Science ®Google Scholar
• Gilkes DM, Semenza GL, Wirtz D. 2014. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 14:430–439.
   PubMed Web of Science ®Google Scholar
• Ho TH, Serie DJ, Parasramka M, Cheville JC, Bot BM, Tan W, Wang L, Joseph RW, Hilton T, Leibovich BC, et al. 2017. Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. Ann Oncology: Official J Eur Soc Med Oncol. 28:604–610.
   PubMed Web of Science ®Google Scholar
• Jeanne A, Untereiner V, Perreau C, Proult I, Gobinet C, Boulagnon-Rombi C, Terryn C, Martiny L, Brezillon S, Dedieu S. 2017. Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide. Sci Rep. 7:7700.
   Web of Science ®Google Scholar
• Kang Y, Zhang R, Suzuki R, Li SQ, Roife D, Truty MJ, Chatterjee D, Thomas RM, Cardwell J, Wang Y, et al. 2015. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Laboratory Investig J Techn Methods Pathol. 95:207–222.
   Web of Science ®Google Scholar
• Karamanou K, Franchi M, Piperigkou Z, Perreau C, Maquart FX, Vynios DH, Brezillon S. 2017. Lumican effectively regulates the estrogen receptors-associated functional properties of breast cancer cells, expression of matrix effectors and epithelial-to-mesenchymal transition. Sci Rep. 7:45138.
   PubMed Web of Science ®Google Scholar
• Krupp M, Maass T, Marquardt JU, Staib F, Bauer T, Konig R, Biesterfeld S, Galle PR, Tresch A, Teufel A. 2011. The functional cancer map: a systems-level synopsis of genetic deregulation in cancer. BMC Med Genomics. 4:53.
   PubMed Web of Science ®Google Scholar
• Li X, Kang Y, Roife D, Lee Y, Pratt M, Perez MR, Dai B, Koay EJ, Fleming JB. 2017. Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth. Oncogene. 36:5432–5438.
   Web of Science ®Google Scholar
• Lu P, Weaver VM, Werb Z. 2012. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 196:395–406.
   PubMed Web of Science ®Google Scholar
• Mao W, Luo M, Huang X, Wang Q, Fan J, Gao L, Zhang Y, Geng J. 2019. Knockdown of lumican inhibits proliferation and migration of bladder cancer. Translational Oncology. 12:1072–1078.
   Web of Science ®Google Scholar
• Mariani A, Wang C, Oberg AL, Riska SM, Torres M, Kumka J, Multinu F, Sagar G, Roy D, Jung DB, et al. 2019. Genes associated with bowel metastases in ovarian cancer. Gynecol Oncol. 154:495–504. Epub 2019/06/18.
   PubMed Web of Science ®Google Scholar
• Meyer HJ, Wilke H. 2011. Treatment strategies in gastric cancer. Deutsches Arzteblatt International. 108:698–705.; quiz 706.
   PubMed Web of Science ®Google Scholar
• Molaei F, Forghanifard MM, Fahim Y, Abbaszadegan MR. 2018. Molecular signaling In tumorigenesis of gastric cancer. Iran Biomed J. 22:217–230.
   PubMedGoogle Scholar
• Mu QM, He W, Hou GM, Liang Y, Wang G, Li CL, Liao B, Liu X, Ye Z, Lu JL, et al. 2018. Interference of lumican regulates the invasion and migration of liver cancer cells. Sichuan Da Xue Xue Bao Yi Xue Ban. 49:358–363.
   Google Scholar
• Nikitovic D, Berdiaki A, Zafiropoulos A, Katonis P, Tsatsakis A, Karamanos NK, Tzanakakis GN. 2008. Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. The FEBS Journal. 275:350–361.
   PubMed Web of Science ®Google Scholar
• Nikitovic D, Katonis P, Tsatsakis A, Karamanos NK, Tzanakakis GN. 2008. Lumican, a small leucine-rich proteoglycan. IUBMB Life. 60:818–823. Epub 2008/10/25.
   PubMed Web of Science ®Google Scholar
• Quan F, Chen Y, Hao D, Zhang L, Yang W. 2017. Epigenetic silence of lumican inhibits the motility of colon cancer via inactivating MAPK signaling in vitro and in vivo. Int J Clin Exp Med. 10.
   Web of Science ®Google Scholar
• Rawla P, Barsouk A. 2019. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 14:26–38.
   PubMed Web of Science ®Google Scholar
• Schaefer L, Iozzo RV. 2012. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev. 22:56–57.
   PubMed Web of Science ®Google Scholar
• Seomun Y, Joo CK. 2008. Lumican induces human corneal epithelial cell migration and integrin expression via ERK 1/2 signaling. Biochem Biophys Res Commun. 372:221–225.
   PubMed Web of Science ®Google Scholar
• Sharma B, Ramus MD, Kirkwood CT, Sperry EE, Chu PH, Kao WW, Albig AR. 2013. Lumican exhibits anti-angiogenic activity in a context specific manner. Cancer Microenviron: Off J Int Cancer Microenviron Soc. 6:263–271.
   PubMedGoogle Scholar
• Song W, Lv CG, Miao DL, Zhu ZG, Wu Q, Wang YG, Chen L. 2018. Development and validation of a nomogram for predicting survival in patients with gastrointestinal stromal tumours. Eur J Surg Oncol. 44:1657–1665.
   Web of Science ®Google Scholar
• Wang X, Zhou Q, Yu Z, Wu X, Chen X, Li J, Li C, Yan M, Zhu Z, Liu B, et al. 2017. Cancer-associated fibroblast-derived lumican promotes gastric cancer progression via the integrin beta1-FAK signaling pathway. Int J Cancer. 141:998–1010.
   Web of Science ®Google Scholar
• Yang CT, Li JM, Chu WK, Chow SE. 2018. Downregulation of lumican accelerates lung cancer cell invasion through p120 catenin. Cell Death Dis. 9:414.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu Z, Xu X, Zhang B, Wu H, Wang M, Zhang X, Yang T, Cai J, Yan Y, et al. 2014. SALL4, a novel marker for human gastric carcinogenesis and metastasis. Oncogene. 33:5491–5500.
   PubMed Web of Science ®Google Scholar
• Zhou K, Ge M. 2013. Effect of lumican gene over-expression on proliferation of lung adenocarcinoma cell A549 and its mechanism. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 29:492–495. 497. Epub 2013/05/07.
   Google Scholar